Cover Image
市場調查報告書

全球庫欣氏症候群治療藥市場

Global Cushing's Syndrome Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 318844
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
全球庫欣氏症候群治療藥市場 Global Cushing's Syndrome Therapeutics Market 2015-2019
出版日期: 2014年11月12日 內容資訊: 英文 69 Pages
簡介

全球庫欣氏症候群治療藥市場,預計在2014∼2019年,以年複合成長率9.41%擴大。庫欣氏症候群女性比男性發現更多症狀,也稱為腎上腺皮質功能亢進症。

本報告提供全球庫欣氏症候群治療藥市場現狀與今後的成長預測、市場規模、各地區趨勢、加入此市場的主要供應商趨勢等彙整資料。

第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

  • 市場概要
  • 產品介紹

第4章 產品簡介

  • Signifor
  • Korlym
  • Ketoconazole HRA

第5章 市場調查方法

  • 市場調查流程
  • 調查方法

第6章 簡介

第7章 疾病概要

  • 疾病的理解
  • 病因與病理學
  • 發病率和罹患率
  • 庫欣氏症候群的診斷
  • 庫欣氏症候群的管理
  • 因庫欣氏症候群的經濟負擔

第8章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各類藥物市場區隔

  • 糖皮質素受體
  • 生長抑制素類似體
  • 皮質醇合成抑制劑
  • 其他

第10章 各給藥途徑市場區隔

  • 口服
  • 非口服

第11章 各劑型市場區隔

  • 固體
  • 液體

第12章 各地區市場區隔

第13章 購買標準

第14章 市場成長的促進要素

第15章 促進要素與其影響

第16章 市場課題

第17章 促進要素的影響與課題

第18章 市場趨勢

第19章 趨勢與其影響

第20章 供應商環境

  • 競爭模式
    • 主要消息
    • 合併、收購
  • 市場佔有率分析
    • Novartis
    • Corcept Therapeutics
    • HRA Pharma
  • 其他值得注意的供應商

第21章 產品研發線

  • 開發平台候補相關主要的資訊
    • LCI-699
    • COR-003
    • Cabergoline
    • ISIS-GCCRRx
    • DG-3173

第22章 主要供應商分析

  • Corcept Therapeutics
  • HRA Pharma
  • Novartis

第23章 本系列的其他報告

圖表

目錄
Product Code: IRTNTR4695

About Cushing's Syndrome

Cushing's syndrome is a condition caused by the prolonged exposure to very high levels of cortisol. This can occur because of the consumption of glucocorticoid drugs or diseases that result in excess cortisol, ACTH, and CRH secretion. Harvey Cushing described the pathophysiology of this condition in 1932. It is more common in women than in men. Cushing's syndrome is also known as hypercortisolism, hypercorticism, hyperadrenocorticism, or Itsenko-Cushing syndrome. Some of the common symptoms of Cushing's syndrome are increase in weight, facial acne, cognitive disorders, and vulnerability to superficial fungus infections, growth of a mass around the collarbone or back of the neck, commonly known as the "buffalo hump," and puffy face or "moon face". Other symptoms include sweating, polyuria, and hypertension, dilation of the capillaries, thinning of the skin, red striae, osteoporosis, diabetes mellitus, immune suppression, sleep disturbances, muscle weakness, hirsutism, baldness, and hypocalcemia. Cushing's syndrome can broadly be classified into corticotropin-dependent Cushing's syndrome and corticotropin-independent Cushing's syndrome.

TechNavio's analysts forecast the Global Cushing's Syndrome Therapeutics market to grow at a CAGR of 9.41 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Cushing's Syndrome Therapeutics market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used in the treatment of Cushing's syndrome caused in humans.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cushing's Syndrome Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Cushing's Syndrome Therapeutics market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global BI and Analytics Platform market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Corcept Therapeutics
  • HRA Pharma
  • Novartis

Other Prominent Vendors

  • Aspireo Pharmaceuticals
  • Cortendo
  • ElexoPharm
  • Ipsen
  • Isis Pharmaceuticals
  • Orphagen Pharmaceuticals
  • Samaritan Pharmaceuticals

Market Driver

  • Presence of Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • Adverse Effects of Drugs
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Signifor
    • 04.1.2. Korlym
    • 04.1.3. Ketoconazole HRA

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

    • 07.1.1. Understanding the Disease
    • 07.1.2. Etiology and Pathophysiology
    • 07.1.3. Rate of Incidence and Prevalence
    • 07.1.4. Diagnosis of Cushing's Syndrome
    • 07.1.5. Management of Cushing's Syndrome
    • 07.1.6. Economic Burden due to Cushing's Syndrome

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Class of Drugs

  • 09.1. Glucocorticoid Receptor Antagonist
  • 09.2. Somatostatin Analog
  • 09.3. Cortisol Synthesis Inhibitor
  • 09.4. Others

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Novartis
    • 20.2.2. Corcept Therapeutics
    • 20.2.3. HRA Pharma
  • 20.3. Other Prominent Vendors

21. Pipeline Portfolio

  • 21.1. Key Information for the Pipeline Candidates
    • 21.1.1. LCI-699
    • 21.1.2. COR-003
    • 21.1.3. Cabergoline
    • 21.1.4. ISIS-GCCRRx
    • 21.1.5. DG-3173

22. Key Vendor Analysis

  • 22.1. Corcept Therapeutics
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Recent Developments
    • 22.1.4. SWOT Analysis
  • 22.2. HRA Pharma
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Therapeutic Areas
    • 22.2.4. Business Strategy
    • 22.2.5. Recent Developments
    • 22.2.6. SWOT Analysis
  • 22.3. Novartis
    • 22.3.1. Key Facts
    • 22.3.2. Business Description
    • 22.3.3. Business Segmentation
    • 22.3.4. Revenue by Business Segmentation
    • 22.3.5. Revenue Comparison 2012 and 2013
    • 22.3.6. Sales by Geography
    • 22.3.7. Business Strategy
    • 22.3.8. Key Developments
    • 22.3.9. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Etiology of Cushing's Syndrome
  • Exhibit 3: Diagrammatic Representation of Cortisol Secretion and its Feedback Loop
  • Exhibit 4: Causes of Cushing's Syndrome
  • Exhibit 5: Diagnosis Algorithm of Cushing's Syndrome
  • Exhibit 6: Global Overactive Bladder Therapeutics Market 2015-2019 (US$ million)
  • Exhibit 7: Global Cushing's Syndrome Therapeutics Market Segmentation by Class of Drugs
  • Exhibit 8: Global Cushing's Syndrome Therapeutics Market by Class of Drugs 2014
  • Exhibit 9: Global Cushing's Syndrome Therapeutics Market Segmentation by Route of Administration
  • Exhibit 10: Global Cushing's Syndrome Therapeutics Market by Route of Administration 2014
  • Exhibit 11: Global Cushing's Syndrome Therapeutics Market Segmentation by Dosage Form
  • Exhibit 12: Global Cushing's Syndrome Therapeutics Market by Dosage Form 2014
  • Exhibit 13: Global Overactive Bladder Therapeutics Market by Geographical Segmentation 2014
  • Exhibit 14: Global Cushing's Syndrome Therapeutics Market Share Analysis 2014
  • Exhibit 15: Snapshot of Pipeline Drugs 2014
  • Exhibit 16: Study Count of Cushing's Syndrome Clinical Trials
  • Exhibit 17: Study Count of Cushing's Syndrome Clinical Trials
  • Exhibit 18: Novartis AG: Business Segmentation
  • Exhibit 19: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 20: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 21: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 22: HRA Pharma: Therapeutic Areas
Back to Top